lystn

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Advances in HFrEF: Slowing a Poor Hospital Prognosis, Part 1- Stratifying Risk Podcast

Featuring James L. Januzzi Jr., MD, FACC, FESC as faculty, moderated by Alanna Morris, MD, MSc, FHFSA, FACC, FAHA.

Summary

In this 2-part educational podcast series, Dr. James Januzzi and Dr. Alanna Morris discuss new therapies and treatment strategies for management of patients with HF and reduced ejection fraction (HFrEF). In part 1, the faculty review aspects of risk stratification in patients with HFrEF and why stratifying risk for these patients is so important.

Heart failure (HF) accounts for around one million hospitalizations in the United States every year, and approximately 50% of these are caused by HF with reduced ejection fraction (HFrEF). Optimal care for patients with HFrEF continues to be refined with the recent advancements in drug and device therapies that can reduce the incidence of cardiovascular (CV) death or hospitalization and improve the prognosis of patients with HFrEF. Clinicians need updated information regarding these recent advancements, when and how to use them, and recommendations for adhering to guideline-directed medical therapies (GDMT) for HF.

This podcast was recorded and is being used with the permission of the presenters.

Learning Objective

Upon completion of this activity, learners should be able to:

• Identify disease and patient characteristics that increase the risk of re-hospitalization or CV death in people with heart failure

This activity is accredited for CME/CE credit.
 
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Advances in HFrEF: Slowing a Poor Hospital Prognosis, Part 1- Stratifying Risk Podcast

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.